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Abstract
Background: Benign prostatic hyperplasia (BPH) constitutes a major clinical problem. Minimally invasive
therapies for the treatment of symptomatic BPH include Transurethral Needle Ablation (TUNA), but it is
unclear what impact this technique has on the disease and its role among other currently available
therapeutic options. The objective of this study is to ascertain the efficacy and safety of TUNA in the
treatment of BPH.
Methods: Systematic review of the literature until January 2005 and meta-analysis of clinical studies
assessing TUNA in symptomatic BPH. Studies were critically appraised. Estimates of effect were calculated
according to the random-effects model.
Results: 35 studies (9 comparative, 26 non-comparative) were included. Although evidence was limited
by methodological issues, the analysis of relevant outcomes indicates that while TUNA significantly
improves BPH parameters with respect to baseline, it does not reach the same level of efficacy as TURP
in respect to all subjective and objective variables. Further, its efficacy declines in the long-term with a rate
of secondary-treatment significantly higher than of TURP [OR: 7.44 (2.47, 22.43)]. Conversely, TUNA
seems to be a relatively safe technique and shows a lower rate of complications than TURP [OR:0.14 (0.05,
0.14)] with differences being particularly noteworthy in terms of postoperative bleeding and sexual
disorders. Likewise, TUNA has fewer anesthetic requirements and generates a shorter hospital stay than
TURP [WMD: -1.9 days (-2.75, -1.05)]. Scarce data and lack of replication of comparisons hinder the
assessment of TUNA vs. other local therapies. No comparisons with medical treatment were found.
Conclusion: The body of evidence on which TUNA has been introduced into clinical practice is of only
moderate-low quality. Available evidence suggest that TUNA is a relatively effective and safe technique
that may eventually prove to have a role in selected patients with symptomatic BPH. TUNA significantly
improves BPH parameters with respect to baseline values, but it does not reach the same level of efficacy
and long-lasting success as TURP. On the other hand, TUNA seems to be superior to TURP in terms of
associated morbidity, anesthetic requirements and length of hospital stay. With respect to the role of
TUNA vis-à-vis other minimally invasive therapies, the results of this review indicate that there are
insufficient data to define this with any degree of accuracy. Overall cost-effectiveness and the role of
TUNA versus medical treatment need further evaluation.
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Background
Benign prostatic hyperplasia (BPH), constitutes one of the
most common and upsetting disorders among the male
population [1-4]. It is associated with lower urinary tract
symptoms that interfere with the activities of daily living
and sleep patterns, significantly reducing quality of life
[2,4] and generating a major burden of sickness and eco-
nomic cost, both direct and indirect, for society [3,5].
These costs are expected to increase in future due to the
longevity of the population and a growing demand for
treatment [3,6,7].
The therapeutic options for symptomatic BPH are phar-
macological and surgical [1,2,6,7]. Medical treatment
often constitutes the initial therapy preferred by patients
and health professionals [3,7,8]. However, it is not effec-
tive in all patients and some have to stop the treatment
owing to the presence of adverse effects [2,7]. Regarding
surgical therapies, Transurethral Resection (TURP) consti-
tutes the principal intervention for BPH, to the point
where it is now viewed as the standard procedure [2,3,6].
However, TURP is not a suitable form of treatment for
some patients, associates with a relatively high morbidity
rate and it is not successful in all patients [1,2,9]. Addi-
tionally, the high cost generated by this therapy is an
important issue for health care providers worldwide [3,5].
In recent years some potentially less invasive procedures
such as Transurethral Needle Ablation (TUNA) have
become available. The TUNA system consists of a radiof-
requency generator, an optical system, and disposable
monopolar catheters. The system applies low-level radiof-
requency energy (460 kHz) directly to the hyperplastic tis-
sue to produce selective necrosis whilst preserving the
urethra and other adjoining structures [10,11]. The proce-
dure was first used in 1993 [10].
TUNA is becoming seen as a possible alternative to con-
ventional treatments -TURP in particular- for sympto-
matic BPH and is being increasingly used in clinical
practice [3]. However, while there are data, including the
results of a small-scale recent meta-analysis, which indi-
cate that it may be a good therapeutic option [10,12,13],
to date there have been no well-founded conclusions as to
its long-term efficacy and safety as stated both by current
guidelines on BPH [2,6,14], and the reports of the existing
systematic reviews on the topic [15-17], and it is thus still
viewed by some authors and institutions as a technique in
the research stage [14,16-18].
Accordingly, this study sought was to analyse the collected
body of evidence regarding the efficacy and safety of
TUNA and its role among currently available therapeutic
modalities for the treatment of symptomatic BPH.
Method
For the identification of studies, we performed a system-
atic review of the literature [19], without language restric-
tions, until January 2005 involving the following
databases: Medline; CINAHL, CC Search Life/Clin, Pollu-
tion & Toxicology, The Cochrane Library, British Library
Inside Conference, Serline, Biomedical Journals, Medi-
conf: Medical Conferences and Events, ISI proceedings.
The search strategy has been: #1 (prostat*) #2 (hyper-
plas*) OR (benign*) OR (BPH), #3 (transurethral needle
ablation) OR (TUNA) OR (transurethral) OR (needle) OR
(ablat*). Hand searching of the reference lists of included
studies and reviews was undertaken and contact was made
with experts in the field. However, no contact was made
with industry.
Selection of studies
For inclusion, the studies were required to meet the fol-
lowing criteria [20-22]: a) Design: studies conducted in 10
or more patients that contained relevant primary clinical
data; b) Population: patients with symptomatic BPH; c)
Intervention: TUNA; d) Comparator: any other medical or
surgical procedure; e) Outcomes: the studies were
required to include quantitative information relating to at
least one of the following primary interest variables:
symptom score, quality-of-life score, maximum urinary
flow rate (Qmax), post-void residual volume (PVR), pres-
sure-flow studies, need for new therapeutic interventions,
adverse effects. The use of health care resources was
included as secondary variable. Two independent review-
ers carried out study selection and data extraction. A third
reviewer checked the resulting extractions and the team
resolved any discrepancies.
Quality assessment
Methodological quality was evaluated for each selected
paper using previously validated guidelines [19].
Data analysis
Intercooled Stata 8 computer software (StataCorp LP
Texas USA 1984–2005) was used to obtain an overall
measure of the effect of TUNA on the outcomes of inter-
est. Quantitative combination of results was made only
when studies showed analogy in terms of type of interven-
tion and clinical homogeneity. We used as a definition of
clinical homogeneity that trials have fixed and clearly
defined inclusion criteria and fixed and clearly defined
outcomes [23]. The meta-analysis was conducted using a
random-effects model. Dichotomous outcomes were ana-
lyzed using Odds Ratio (OR) or expressed as proportions
with their corresponding 95% confidence interval. Con-
tinuous variables were analyzed as the difference in means
(with 95% confidence interval) between pre- and post-
treatment values at the respective assessment dates, with
the difference in variances being estimated using standardBMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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formulae [24]. In cases where the original study solely fur-
nished the mean of a continuous variable, standard devi-
ation was attributed by weighting the standard deviations
of the selfsame variable in other studies [24]. Difference in
means was calculated as Weighed Mean Difference
(WMD) but when different methods of measurement
were used among the studies- such as in symptom scores-
we used Standardized Mean Difference (SMD). Statistical
heterogeneity was analyzed using the X2 statistic with a P
value of < .05. Sensitivity analyses were performed to
assess the influence of methodological issues, such as
study design, on the overall effect estimation. Absolute
Risk Reduction and the Number Needed to Treat (NNT)
were estimated where appropriate. The NNT was calcu-
lated using the Internet-accessible Visual Rx program
http://www.nntonline.net. Where it proved impossible
for meta-analytic techniques to be implemented owing to
the characteristics of the studies or their manner of
expressing the results, an individual analysis was per-
formed. Results were calculated on the basis of the respec-
tive studies' initial populations, provided that this was
possible and a P value of < .05 was deemed significant.
Results
After eliminating redundancies arising from the use of
several databases and studies that failed to report primary
clinical outcomes, there were 35 studies that fulfilled the
inclusion criteria. From them, 26 were non-comparative
and 9 comparative studies. Their respective characteristics,
methodological quality and results are outlined separately
below. No study that compared the efficacy and safety of
TUNA with medical treatment was identified.
A. Non-comparative studies
Table 1 contains a summary of the 26 studies included.
Although a number of efforts were made to prevent any
possible duplication of patients, this cannot be entirely
ruled in some studies [39,48]. In general, patients were
diagnosed as having symptomatic BPH with a symptom
duration of over 3 months. Whereas some studies solely
included patients with acute refractory urinary retention
[26,30,31], other authors [29,47] specifically considered
this a criterion of exclusion. In contrast, while median
lobe hypertrophy was generally deemed to be an exclu-
sion criterion for TUNA, 2 studies [40,45] typically
included this group of patients. Thirteen studies [26,28-
30,33,35,36,38,41,43,46,48,49] furnished data on base-
line prostatic size, with the mean value being 45.5 ± 8.8
(range:38–66). Only 3 studies [42,44,49] had follow-up
periods exceeding 2 years. Only 4 studies [26,33,39,45]
expressly stated that industry had been the source, totally
or partially, of funding.
In terms of grades of scientific evidence, these were level-
IV studies. Even so, study quality, based on the principle
of methodologic biases, was acceptable. As shown in
Table 1, most were prospective studies, used clear and, in
general, homogeneous inclusion and exclusion criteria,
plus outcome measures, objective as well as subjective,
that were validated and likewise homogeneous. Conse-
quently, selection, performance and detection risks would
thus appear to be relatively small. Nevertheless, none con-
tained an express statement to the effect that assessment
of results had been performed blindly or independently.
Furthermore, despite the fact that some studies reported a
scant number of losses to follow-up, in others this
number was considerable or unspecified.
Efficacy
As Table 2 shows, TUNA led to a significant improvement
on both subjective and objective variables over pre-inter-
vention values. Thus, TUNA reduces the symptom index
and quality-of-life score by 50%-60% with respect to pre-
treatment values, an improvement that is maintained
across follow-up, though a progressively downward trend
is in evidence after 3 years. With respect to the objective
parameters, TUNA leads to improvements which, though
significant, amount to an increase of no more than 30–
35% over baseline values. Its effect, albeit significant from
a statistical point of view, is poorer in term of improve-
ment of urodynamic parameters (Table 2). In some varia-
bles (Qmax, PVR) a delayed improvement in outcomes is
observed, which in all likelihood is the result of a reduc-
tion in the number of patients analyzed and may there-
fore not signal any new real improvement. Combined
analysis of 4 studies [30,33,35,39] showed that in most
patients (approximately 80%) there were no notable
changes in sexual function following the procedure.
Some authors [28] state that the effect on objective varia-
bles is weaker in the case of prostates larger than 50 grams.
Others, however, do not observe that size exerts a signifi-
cant influence on their patients' response and suggest that
this should not be an exclusion factor for the use of the
system [36,38]. Additionally, the results of five studies
[25,26,30,31,47] indicated that 70% of patients (78/112)
with acute/chronic urinary retention achieved spontane-
ous voiding in the first week post-procedure. In like fash-
ion, studies that analyze the effect of TUNA on patients
with median lobe enlargement [40,45] report improve-
ments similar to those among the general population with
symptomatic BPH
Few studies have endeavored to identify the factors impli-
cated in response to treatment and its results indicate the
absence of significant differences between patients who
do and do not respond to the treatment, in terms of age,
prostatic volume, objective or subjective mean baseline
scores, position of TUNA needles, number of lesions, or
temperature attained [36].BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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Seventeen studies [26,28,30,31,34-36,38,41-49] give data
on the need for new interventions and, though their indi-
vidual results varied widely, combined analysis indicates
that 237 of 1036 patients treated with TUNA required new
treatments, amounting to an overall re-treatment rate of
19.07% (95% CI:18.7–39.7) (Figure 1). These new treat-
ments fundamentally consisted of surgical measures,
namely: TURP (150 cases); unspecified surgery (22); sec-
ond TUNA (7); prostatectomy (6); and transurethral inci-
sion of the prostate (1). A total of 41 patients received
drug therapy. In 10 cases, the treatment employed was not
specified.
Safety
The description of adverse effects was heterogeneous and
in general ambiguous. Table 3 lists the adverse effects
identified in the individual studies. Due to the fact that 4
studies did not include data on safety [10,41,42,49], the
percentage calculation was based on 1204 patients
included in the 22 studies that did furnish such data.
As shown by this table, the most frequent adverse effect
was hematuria, which in most cases took the form of mild
bleeding. Overall, the series described a total of 16 cases
of severe hematuria, with only one patient requiring trans-
Table 1: Summary of the characteristics of the non-comparative studies (n = 26)
Characteristics Mean (range) Frequency studies/patients (%)
Sample size 59 (range:10–206)
Age (years) 67.5 ± 2.9 (47–90)
Follow-up (months) [n] 16 ± 15 (1–63)
Continent 
Europe 13 (50%)
America 6 (23%)
Asia 3 (11.5%)
Australia 3 (11.5%)
Africa 1 (4%)
Studies in languages other than English 3 (11.5%)
Type of study 
Design
Prospective 24 (92%)
Retrospective 1 (4%)
Unknown 1 (4%)
Single-center 17 (65.4%)
Multicenter 9 (34.6%)
Type of anesthesia 
Local 3 (13%)
Local+sedation 10 (43.5%)
Spinal 3 (13%)
General 2 (8.7%)
General/local+sedation 5 (22%)
Variables assessed
Symptoms 25 (96.2%)
Quality of life score 22 (84.6%)
Qmax (mL/s) 25 (96.2%)
PVR (mL) 17 (65.4%)
Sexual function 12 (46.2%)
Pressure-flow studies 7 (26.9%)
Prostatic size 13 (50%)
Re-treatment 17 (65.4%)
Adverse effects 22 (84.6%)
Duration of procedure 15 (57.7%)
Hospital stay 11 (42.3%)
Quality assessment 
Consecutive or representative sample Yes: 21 No: 3 Not reported:2
Presence of cointerventions Yes: 19 No: 1 Not reported:6
Evaluation blind or independent Yes: 0 No: 26 Not reported:0
Losses to follow-up ≥ 20% Yes:11 No:9 Not reported:6BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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Table 2: Efficacy of TUNA. Non-comparative studies
3 months 6 months 1 year 2 years 3 years 4 years 5 years
Symptom index
Studies 1426,28–30,32,33,35,36,38,43,45–48 1425,26,28–30,32,33,35,36,38,39,41,43,45 1330,32–36,38,39,41,43–45, 47 432,36,43,44 242,44 144 244,49
No. patients 650 661 868 403 297 206 394
Effect -11.33 -12.52 -12.59 -12.98 -9.94 -10.2 -10.99
95% CI -14.1,-8.6 -15, -9.9 -14, -11.4 -14.2,- 11.8 -10, -9 -11,-9. -14,- 8.3
P-value .000 .000 .000 .000 .000 .000 .000
%improvement 53% 59% 59% 61% 47% 48% 51%
Quality-of-life score
Studies 1226,28,30,32,33,35,36,38,43,45,47,48 1325,26,28,30,32,33,35,36,38,39,41,43,45 1430,32–36,38,39,41,43–47 532,36,43,44,46 144 144 244,49
No. patients 545 646 959 496 206 206 394
Effect -2.80 -2.79 -2.60 -2.51 -2.1 -1.9 -2.14
95% CI -3.3, -2.3 -3.2,-2.4 -3, -2.15 -2.8, -2.23 ‡ ‡ -3.2, -1.
P-value .000 .000 .000 .000 ‡ ‡ .000
%improvement 60% 60% 56% 54% 45% 41% 46%
Qmax (mL/s)
Studies 1525,26,28–30,33,35–38,43,45–48 1725,26,28–30,32–39,41,43,45,46 1430,32–36,38,39,41,43–47 432,36,43,44 242,44 144 244,49
No. patients 578 817 960 403 297 206 394
Effect 5.381 5.32 4.40 5.029 3.48 4.10 3.53
95% CI 3.67,7.08 3.7, 6.9 2.94, 5.86 4.35, 5.7 1.5, 5.4 3.2, 4.9 2.9, 4.2
P-value .000 .000 .000 .000 .001 .000 .000
%improvement 33% 34% 45% 37% 57% 49% 56%
PVR (mL)
Studies 1128,29,33,35–38,43,45,47,48 1028,29,33,35,36,38,39,43,45,46 1033–36,38,39,43,45,47 245,52 NA NA 149
No. patients 440 557 598 77 188
Effect -29.55 -37.6 -32.10 -29.5 -58
95% CI -38.9, -20 -49.7,-25.5 -44,-20 -47.5,- 11.5 -76,-40
P-value .000 .000 .000 .001 .000
%improvement 28% 36% 31% 28% 56%
Pdet at Qmax (cm H2O)
Studies 332,35,36 726,29,30,32,35–37 232,36 232,36 NA NA NA
No. patients 238 247 167 167
Effect -24.64 -25.36 -22.74 -24.48
95% CI -35.6,-13.6 -33.2,-17.5 -29.5, -16 -40, -8.92
P-value .000 .000 .000 .002
%improvement 28% 29% 25% 28%
Prostatic size
Studies 726,28,31,33,35,43,48 529,33,41,43,46 430,33,43,46 143 NA NA 149
No. patients 242 257 140 8 131
Effect -6.32 -6.45 -7.89 -7.9 1.9
95% CI -9.1,-3.5 -9.6,-3.3 -10.6,-5.1 -17.7,1.9 -3.4,7.2
P-value .00 .00 .00 .11 .48
% reduction 14% 14% 17% 17% 0%
Random effects model. Results are expressed as difference of means and percentage of improvement versus baseline. Abbreviations: CI denotes 
confidence interval. Qmax denotes maximum urinary flow rate. PVR: Post-void residual volume.‡ impossible to calculate due to lack of data. NA: not 
availableBMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
Page 6 of 17
(page number not for citation purposes)
fusion. In contrast, 279 cases of urinary retention were
described, which proved transitory in all but two cases.
Attention should be drawn to the variability of outcomes
in the 18 individual studies reporting this adverse effect, a
variability that seems to be due, on the one hand, to the
different patient-selection criteria employed and, on the
other, to the practice of using or not using routine post-
operative catheterization. Also appearing with considera-
ble frequency were dysuria, of lesser or greater intensity;
irritative symptoms, which were usually transitory but
were not clearly described and; urinary tract infections.
With respect to adverse effects on sexual function, Table 3
lists the scant number of cases registered.
Only a very small number of studies mentioned the pres-
ence of adverse effects during the procedure. Kahn [38]
reported the existence of intense pain during the proce-
dure in 4 patients under the age of 65 years, which caused
the TUNA to be halted in two cases, and was resolved by
means of perineal block in the other two. This same
author described that 10 patients reported a medium-
moderate burning sensation, which in two cases made it
necessary for the treatment to be halted. Roehrborn [39]
stated that 22% of patients analyzed reported pain and
discomfort, and Dæhlin [47] observed that 42% of his
patients presented with moderate and 4% with major
malaise.
Use of healthcare resources
In 43.5% of studies the procedure was performed under
local anesthesia and conscious sedation with an estimated
mean duration of 45 ± 18 minutes. Insofar as hospital stay
was concerned, 12 studies furnished quantitative data. In
9 of these, the stay was less than a day, in one it was 1 day,
and in two it was more than 2 days. With respect to the
number of patients included in these studies, 87% of
patients remained in hospital for just a few hours after
TUNA had been performed. No study formally analyzed
the costs of the procedure.
B. Comparative studies
All studies compared TUNA with TURP whereas 4 com-
pared TUNA with other minimally invasive techniques
such as: Transurethral Microwave Thermotherapy
(TUMT), Water-induced Thermotherapy (WIT), Intersti-
tial Laser Coagulation (ILC), Transurethral Electrovapori-
zation (TUVP), Visual Laser Ablation (VLAP) and
Transrectal High Intensity Focused Ultrasound (HIFU).
In terms of design, 4 were non-randomized and 5 were
randomized studies. Of these, three [50,51,54] were
papers based on a single clinical trial. Nevertheless, it was
decided that all should be included since they furnished
information on different variables and follow-up periods.
Bearing this in mind, the number of patients included in
the randomized studies was 336 (167 treated with TUNA,
169 with TURP). Their general and methodologic charac-
teristics are shown in Table 4. In line with these character-
istics and biases, these studies provide level-II evidence.
In addition, we identified 4 non-randomized studies
(level-III evidence) [55-58]. Of the two papers by Schaltz
which correspond to a single study, the more complete
[57] was used for analysis of efficacy. We also decided to
include the 1997 paper [55], since it furnished safety data
that were not included in the later paper. The characteris-
tics of these studies are set out in Table 4. Allocation to
each treatment arm was made in line with the wishes of
the patient [56], sequentially [55,57] or in accordance
with anesthetic risk, prostatic volume and the patient's
desire to maintain normal ejaculation [58].
1. TUNA vs. TURP
Clinical efficacy
The results of comparisons are shown in Table 5. Both
techniques led to significant improvements in BPH
parameters and initially, the efficacy of TUNA would seem
to be equivalent to that of TURP. However, at 12 months
subjective parameters and objective functional measures
are both statistically better in the latter case, with the dif-
ferences becoming increasingly greater across time. In
some variables a delayed uniformity in results is observed,
which in all likelihood is the result of a reduction in the
number of patients analyzed and may therefore not signal
any new real improvement in the group treated by TUNA.
The combined results of the studies that furnished data
(Figure 2) indicated that TUNA had a re-treatment rate sig-
nificantly higher than that of TURP given that 10% (21/
TUNA.Non-comparative studies. Rate of secondary inter- ventions Figure 1
TUNA. Non-comparative studies. Rate of secondary 
interventions. Random effects model. 
0% 20% 40% 60% 80%
Combined 
                 Zlotta 03 
            Fujimoto 03 
              Daehlin 02 
                 Murai 01 
             Naslund 00 
      Bergamashi 00 
               Namiki 99 
            Holmes 99 
  Namasivayam 99 
                Kahn 98 
              Steele 97 
            Rosario 97 
            Rodrigo 97 
                          Zlotta 96 
                             Millard 96 
                   Schulman 95 
                 Harewood 95 BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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206) of TUNA versus a mere 1% (3/282) of TURP patients
required new treatments.
The effects of treatment on sexual function were analyzed
in 3 studies [50,53,56] that used different scales. In one
randomized clinical trial, Bruskewitz [50], using a 7-item
questionnaire, observed a clearly different response in the
two treatment groups, inasmuch as 53% of the TURP ver-
sus only 13% of the TUNA cohort reported diminution in
the volume ejaculated (P < .001). Cimentepe [53]
observed that 100% of patients treated with TUNA
reported no change whereas 61% of patients treated with
TURP reported deterioration in sexual function. For his
part, Arai [56], in a non-randomized study, observed a
mild-moderate deterioration in erectile function in 26.5%
of subjects treated with TURP and 20% of subjects treated
with TUNA, without there being any significant change in
the pre- and post-treatment indices of erectile function or
libido in either group. In 48.6% and 24% (P < .001) of
TURP and TUNA patients, respectively, there was loss of
ejaculation capacity or an appreciable diminution in the
volume ejaculated.
Safety
There was no mortality associated with either of these pro-
cedures whereas a total of 67 and 417 adverse effects were
reported for the TUNA and TURP groups respectively. The
combined analysis of the results is shown in Figure 3.
In both procedures, irritative symptoms appeared to be
frequent and, though somewhat unclearly described, were
usually transitory. Only one study [53] referred to their
duration, indicating that these remained in evidence for
7–10 days in the case of TUNA and 2–3 weeks in the case
of TURP. Apart from such symptoms, the most frequent
adverse effects were postoperative bleeding and those
linked to sexual dysfunction. Whilst the description of the
presence of postoperative bleeding in TURP patients was
a constant feature of almost all the studies -with one [52]
reporting that up to 10.5% of patients needed transfusion-
not a single case of TUNA was cited as requiring transfu-
sion.
Similarly, adverse effects on sexual function were less fre-
quent in the TUNA group. The studies reviewed described
7 cases of urinary retention in the TUNA and 3 in the
TURP group, a finding that that favors the latter technique
from a statistical point of view. Nevertheless, the differ-
ence observed between studies in routine indication and
duration of post-operative catheterization, coupled with
the poor descriptions given, make this complication diffi-
cult to evaluate.
Table 3: Safety of TUNA. Non-comparative studies
Adverse effect No. events Percentage of total patients
Hematuria:
- Mild 337 28%
- Moderate 85 7%
- Transitory unspecified severity 25 2%
- Severe 16 1%
Transitory urinary retention 279 23%
Dysuria 167 14%
Irritative symptoms 117 10%
Urinary tract infection 43 4%
Pain during procedure
Moderate 11 0.9%
Intense 4 0.3%
Postoperative perineal pain 13 1%
Epidydimo-orchitis 11 0.9%
Mild-moderate burning sensation 10 0.8%
High fever 8 0.7%
Treatment halted due to intolerance to procedure 6 0.5%
Urethral stenosis 6 0.5%
Erectile dysfunction 4 0.3%
Hemospermia 4 0.3%
Retrograde ejaculation 3 0.2%
Loss of ejaculation 1 0.08%
Prostatism 2 0.2%
Complex bladder dysfunction 1 0.08%
Damage in the mucosa 1 0.08%
Deep vein thrombosis 1 0.08%B
M
C
 
U
r
o
l
o
g
y
 
2
0
0
6
,
 
6
:
1
4
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
9
0
/
6
/
1
4
P
a
g
e
 
8
 
o
f
 
1
7
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 4: Summary of the characteristics of studies that compare TUNA with other therapies
Author [reference number]
Bruskewitz [50] Roehrborn [51] Chandrasekar 
[52]
Cimentepe [53] Hill [54] Schatzl [55,57] Arai [56] Minardi [58]
Design  RCT RCT RCT RCT RCT Prospective cohort Prospective cohort Prospective cohort
No. patients 1 2 11 2 11 5 65 9 1 2 19 5 2 0 42 1 2
TUNA [N. 
patients]
65 65 76 26 65 15 51 24
Comparator 
[No. Patients]
TURP [56] TURP [56] TURP [76] TURP [33] TURP [56] TURP [28]
TUVP [17]
VLAP [15]
HIFU [20]
TURP [65]
TUMT [40]
ILC[48]
TURP [90]
TUVP [13]
ILC[71]
WIT [13]
Duration of 
symptoms
> 3months > 3months Not reported Not reported > 3months Not reported Not reported Not reported
Anesthesia TUNA: Local
TURP: General
TUNA: Local
TURP: General
Not reported Regional TUNA: Local
TURP: General
General/Regional TUNA, ILC: Not 
reported
TURP: Spinal
TUMT: Local
TUNA-WIT:Local
TUVP, ILC: Spinal
TURP: General
Variables 
assessed
Symptom, QoL, 
Qmax, PVR, 
prostatic size, 
adverse effects 
duration of 
procedure, hospital 
stay
Pdetat Qmax No. 
Abrams-Griffiths
Symptom, QoL, 
Qmax, adverse 
effects, hospital 
stay, re-treatment
Symptom, QoL, 
Qmax, PVR, sexual 
function, prostatic 
size, adverse 
effects, duration of 
procedure, hospital 
stay, re-treatment
Symptom, QoL, 
Qmax, PVR, 
adverse effects, 
hospital stay, re-
treatment
Symptom, QoL, 
Qmax, PVR, 
adverse effects, 
hospital stay, re-
treatment
Symptom, QoL, 
Qmax, PVR, sexual 
function, adverse 
effects.
Symptom, QoL, 
Qmax, PVR, Pdet at 
Qmax, prostatic 
size, adverse 
effects, duration, 
re-treatment
Follow-up 12 months 6 months 7 years 18 months 5 years 6 weeks/24 m 3 months 24 months
Randomization 
method specified 
Yes Yes No No Not applicable Not applicable Not applicable
Inclusion/
exclusion criteria 
specified
Yes Yes No Yes Yes Yes Yes
Concomitant 
treatment 
specified
Yes Yes No Yes Yes No No
Intention-to-
treat analysis
Yes Yes Not reported Not reported Yes Not reported Not reported
Blind/
Independent 
evaluation 
Not reported Not reported Not reported Not reported Not reported Not reported Not reported
Losses TUNA:9%
TURP:16%
None Not reported None TUNA>72%
TURP > 60%
TUVP [4]
VLAP [4]
HIFU [4]
TUNA [3]
TUNA [9]
TURP [10]
TUMT [6],
ILC [6]
Not reported
Abbreviations: RCT: Randomized controlled trial. TUNA (Transurethral Needle Ablation). TURP (Transurethral resection). TUMT (Transurethral Microwave Thermotherapy). WIT (Water-induced 
Thermotherapy). ILC (Interstitial Laser Coagulation). TUVP (Transurethral Electrovaporization of the Prostate). VLAP (Visual Laser Ablation of the Prostate). HIFU (Transrectal High Intensity 
Focused Ultrasound). QoL: Quality of life score. Qmax: Maximum urinary flow rate. PVR: Post-void residual volume. Pdet at Qmax: Detrusor presures at peak flow rate.BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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Table 5: TUNA vs. TURP: results of meta-analysis of variables of efficacy.
Variable Studies (No. patients) TUNA
Difference in means
(% improvement)
TURP
Difference in means
(% improvement)
TUNA vs. TURP
Difference in means
(95% CI), P value
Symptom score
3 months 350,53,56 (384) -12.49 (57%) -13.85 (64 %) 1.33 (-.81,3.47), .22
1 year 452–54,57 (427) -12.09 (55%) -15.48 (71%) 3.69 (2.09, 5.29), .00
2 years 352,54,57 (368) -10.42 (48%) -14.83 (68%) 4.72 (3.77, 5.69), .00
3 years 252,54 (273) -9.83 (45%) -14.63 (67%) 4.82 (4.25, 5.39), .00
4 years 154 (121) -10.80 (50%) -16.50 (76%) 5.70 (4.67, 6.73), .00
5 years 154 (121) -13.30 (61%) -13.30 (61%) 0 (-0.99, 0.99), 1.0
Quality of life score
3 months 350,53,56 (277) -4.47 (54%) -3.65 (47%) -0.40 (-1.25, 0.45), .35
1 year 352–54 (332) -4.05 (49%) -4.34 (56%) 0.63 (0.12, 1.15), .01
2 years 252,54 (273) -3.90 (47%) -5.67 (74%) 1.69 (-1.05, 4.44), .22
3 years 252,54 (273) -4.17 (50%) -5.18 (67%) 1.02 (0.14, 1.90), .02
4 years 154 (121) -6.6 (80%) -8.90 (116%) 2.3 (1.84, 2.76), .00
5 years 154 (121) -8.0 (96%) -8.60 (112%) 0.6 (0.21, 0.99), .00
Qmax (mL/s)
3 months 350,53,56 (277) 4.85 (57%) 11.37 (148%) -6.48 (-7.29, -5.68), .00
1 year 452–54,57 (375) 6.49 (76%) 12.23 (160%) -5.9 (-7.73, -4.08), 00
2 years 450,54,57,58 (430) 4.55 (53%) 12.17 (159%) -7.93 (-11.1, -4.77), .00
3 years 252,54 (273) 5.6 (66%) 10.80 (141%) -5.32 (-6.78, -3.85), .00
4 years 154 (121) 2.9 (34%) 10.10 (132%) -7.2 (-7.99, -6.4), .00
5 years 154 (121) 2.6 (30%) 9.8 (127%) -7.2 (-7.93, -6.47), .00
PVR (ml)
3 months 350,53,56 (277) -27.76 (31%) -44.66 (44%) 23.82 (-19.35, 66.97), .28
1 year 353,54,57 (223) -21.92 (24%) -52.42 (51%) 24.97 (20.90, 29.05), .00
2 years 354,57,58 (278) -27.58 (31%) -69.24 (68%) 35.8 (25.00, 46.61), .00
5 years 154 (121) -31.40 (35%) -54.50 (53%) 23.1 (12.16, 43.04), .00
PdetQmax (cm of water)
6 months 251,58 (235) -20.52 (27%) -32.4 (45%) 13.12 (0.6, 25.65), .04
2 years 158 (114) -28.56 (38%) -42 (58%) 13.44 (11.6,15.27), .00
No. Abrams-Griffiths
6 months 151 (121) -24 (39%) -47.40 (81%) 23.4 (20.7, 26.2), .00
Prostatic size
3 months 250,58 (235) -2.66 (7%) -12.98 (34%) 10.13 (-7.02,27.3), .02
1 year 150 (121) -0.9 (2.4%) -5.5 (17%) 6.4 (4.8,7.96), .00
2 years 253,58 (173) -6.46 (15%) -12.78 (34%) 5.52 (-2.7,13.75), .19
Random effects model. Results are expressed as difference of means and percentage of improvement versus baseline. Abbreviations: CI denotes 
confidence interval. Qmax denotes maximum urinary flow rate. PVR: Post-void residual volume.BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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As is graphically depicted in Figure 3, treatment with
TUNA resulted in a significantly lower number of compli-
cations than TURP [OR: 0.14 (95% CI:.05-.41)]. This
amount indicates that, overall, TUNA entailed an Abso-
lute Risk Reduction of complications of 19.4% (95%
CI:17%-22%), with an estimated NNT of 5 (95% CI:5–6)
to prevent a bad outcome.
Use of healthcare resources
In 50% of the studies, TUNA was performed under local
anesthesia, with or without associated sedation, whereas
TURP was performed in all cases under general or regional
anesthesia. Regarding the estimated mean duration of the
procedures, the difference was statistically significant in
favour of TUNA [WMD: -13.22 minutes (95% CI:-17.8, -
8.7), P = .00]. Analysis of the 4 studies [52-54,57] that fur-
nished data indicated a hospital stay almost two days
shorter in the TUNA (mean value:1.22 days) than in the
TURP group (mean: 2.84 days), with the difference prov-
ing statistically significant [WMD: -1.9 (95% CI:-2.75, -
1.05), P = .00]. None of the studies conducted any analy-
sis of the costs associated with the respective procedures.
2. TUNA vs. other minimally invasive therapies
The results of these comparisons are shown in Tables 6
and 7. Arai's study [56] showed that, in the assessment at
3 months, TUNA-related improvements were significantly
superior to those of TUMT in terms of symptom index,
quality-of-life score, Qmax and PVR; in addition, there
was a trend, albeit non-significant, towards a lower
number of erectile dysfunctions.
Likewise, TUNA seemed to have a significantly better
effect than WIT on the objective variables analyzed in the
study by Minardi [58]. The results vis-à-vis ILC proved
more difficult to analyze, as each of the techniques
seemed somewhat more effective than the other, depend-
ing on the point in time at which they were evaluated.
However, adverse effects tended to be more frequent in
the group treated with ILC, particularly in the case of irri-
tative symptoms, postoperative hematuria, and reduction
in seminal volume (Table 7).
Analysis of the studies that compared TUNA with TVP
[55,57,58] indicated that TVP achieved improvements sig-
nificantly superior to TUNA in both subjective and objec-
tive variables, but that this was accompanied by a higher
incidence of adverse effects.
As against VLAP, Schatzl's results based on 30 patients
indicated that, while both techniques led to similar
improvements in the symptom index, VLAP exercised a
significantly superior effect on the objective variables
(Qmax and PVR). Furthermore, there seemed to be fewer
adverse effects with this technique. Notable differences
between TUNA and HIFU were not in evidence in the
analysis of the 35 subjects in whom these techniques were
compared.
Discussion
This study analyzes the results of 35 primary studies on
TUNA in the treatment of BPH and, to our knowledge,
represents the most complete systematic review con-
ducted to date, by virtue not only of the number of studies
included, but also of the scope of the variables analyzed
and the length of time covered by the analysis as com-
pared to previous systematic reviews [15-17]. A total of 26
clinical series and 9 comparative studies assessing TUNA
vs. TURP and other minimally invasive techniques such as
Studies that compare TUNA and TURP. Adverse effects.  Results of meta-analysis Figure 3
Studies that compare TUNA and TURP. Adverse 
effects. Results of meta-analysis. Random effects model.  
CI denotes confidence interval.
  Favors TUNA                               Favors TURP 
1
Event  % Weight
Odds ratio
(95% CI)
 0.29 (0.13,0.63) Erectile dysfunction   9.7
 1.66 (0.23,11.96) Dysuria    7.5
 0.26 (0.06,1.20) Urethral stenosis   8.4
 0.03 (0.01,0.06) Retrograde ejaculation   9.8
 0.00 (0.00,0.03) Transitory hematuria   5.5
 0.51 (0.03,10.22) Severe hematuria   5.6
 0.21 (0.05,0.94) Urinary incontinence   8.5
 0.61 (0.21,1.77) Urinary tract infection   9.3
 0.19 (0.01,4.13) Bladder neck obstruction   5.5
 0.14 (0.06,0.35) Loss of ejaculation   9.5
 4.11 (1.04,16.27) Urinary retention   8.7
 0.00 (0.00,0.03) Bleeding   5.9
 0.01 (0.00,0.08) Ejaculation disorders   5.9
 0.14 (0.05,0.41)  Overall (95% CI)
TUNA vs. TURP. Need for new therapeutic interventions Figure 2
TUNA vs. TURP. Need for new therapeutic interven-
tions. Random effects model.  CI denotes confidence inter-
val Chi-squared heterogeneity = 0.70 (d.f. = 4), P = .951. 
Overall effect P value = .000.
    Favors TUNA              Favors TURP 
1
Study
% Weight  Odds ratio
(95% CI) 
 6.75 (0.64,71.71)  Schatzl 2000  21.8
 4.17 (0.45,38.17)  Chandrasekar 2003  24.8
 6.84 (0.31,148.87)  Cimentepe 2003  12.8
 8.84 (1.08,72.13)  Hill 2004   27.6
 20.11 (0.93,433.78)  Minardi 2004   12.9
 7.44 (2.47,22.43)   Overall (95% CI) BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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Table 6: TUNA vs. other minimally invasive therapies. Efficacy
Variable No. studies (patients) TUNA
Difference in means
(% improvement)
TUMT
Difference in means
(% improvement)
TUNA vs. TUMT WMD 
(95% CI), P value
Symptom score
Pre-3 months 156 (76) -9.3 (48%) -5.2 (28%) -4.1 (-5.02, -3.18), .00
Quality-of-life score
Pre-3 months 156 (76) -2.3 (49%) -1.7 (39%) -0.6 (-0.75, -0.44), .00
Qmax (mL/s)
Pre- 3 months 156 (76) 1 (11%) 0.9 (12%) 0.1 (-0.47, 0.67), .73
Variable No. studies (patients) TUNA 
Difference in means
(% improvement)
WIT 
Difference in means
(% improvement)
TUNA vs. WIT 
WMD (95% CI), P value
Qmax (ml/sec
Pre- 6 months 158 (37) 3.2 (41%) 1.8 (14%) 1.4 (-0.13, 2.93), .07
Pre- 2 years 158 (37) 4.9 (44%) 2.2 (18%) 2.7 (1.14, 4.26), .00
PVR (mL)
Pre- 6 months 158 (37) -58.3 (62%) -18.5 (25%) -39.8 (-46.4, -33.2), .00
Pre- 2 years 158 (37) -40.9 (54%) -23.3 (49%) -17.6 (-24, -11.2), .00
Pdet at Qmax (cm H2O)
Pre- 6 months 158 (37) -22.52 (35%) -17.5 (27%) -5.02 (-9.36, -0.65), .02
Pre- 2 years 158 (37) -28.56 (44%) -15.7 (25%) -12.9 (-17.4, -8.34), .00
Variable No. studies (patients) TUNA 
Difference in means
(% improvement)
ILC 
Difference in means
(% improvement)
TUNA vs. ILC 
WMD (95% CI), P value
Symptom score
Pre- 3 months 156 (84) -9.3 (48%) -12.4 (64%) 3.1 (2.36, 3.84), .00
Quality-of-life score
Pre- 3 months 156 (84) -2.3 (49%) -2.5 (58%) 0.2 (0.06, 0.34), .00
Qmax (mL/s)
Pre- 3 months 156 (84) 1 (11%) 5 (53%) -4 (-4.64, -3.36), .00
Pre- 6 months 158 (95) 3.2 (41%) 2.8 (30%) 0.4 (-0.15, 0.95), .15
Pre- 2 years 158 (95) 4.9 (44%) 3 (32%) 1.9 (1.27,2.52), .00
PVR (mL)
Pre- 3 months 156 (84) -22.1 (26%) -71.9 (72%) 49.8 (41.99, 57.60), .00
Pre- 6 months 158 (95) -58 (62%) -45 (45%) -13 (-16.41, -10.2), .00
Pre- 2 years 158 (95) -41 (54%) -42 (42%) 1.3 (-2.07, 4.67), .45BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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Pdet at Qmax (cm H2O)
Pre- 6 months 158 (95) -22.5 (35%) -25.8 (38%) 3.28 (1.4, 5.16), .00
Pre- 2 years 158 (95) -28.6 (44%) -23 (34%) -5.56 (-7.76, -3.36), .00
Variable No. studies (patients) TUNA 
Difference in means
(% improvement)
TUVP 
Difference in means
(% improvement)
TUNA vs. TUVP 
WMD (95% CI), P value
Symptom score
Pre- 6 months 157 (32) -9 (47%) -13.1 (69%) 4.1 (2.38, 5.82), .00
Pre-1 year 157 (32) -11.2 (58%) -13.3 (70%) 2.1 (0.72, 3.48), .00
Pre- 2 years 157 (32) -10 (52%) -12.7 (66%) 2.7 (1.13, 4.27), .00
Qmax (mL/s)
Pre- 6 months 257,58 (69)a 3.42 (41%) 10.25 (108%) -6.08 (-8.6, -3.5), .00
Pre- 1 year 157 (32) 2.6 (30%) 12.4 (132%) -9.8 (-10.97, -8.63), .00
Pre- 2 years 257,58(69)b 2.76 (44%) 8.93 (97%) -6.1 (-11.45, -0.67), .00
PVR (mL)
Pre- 6 months 257,58 (69)c -57.26 (62%) -61.84 (76%) 10.96 (0.26, 21.65), .04
Pre- 1 year 157 (32) -53 (62%) -51 (67%) -2 (-16.15, 12.15), .78
Pre- 2 years 257,58 (69)b -42.06 (54%) -61.20 (74%) 10.87 (-20.54, 42.3), .49
Pdet at Qmax (cm H2O)
Pre- 6 months 158 (37) -22.52 (35%) -40 (53%) 17.48 (13.8, 21.2), .00
Pre- 2 years 158(37) -28.56 (44%) -35 (47%) 6.44 (2.32, 10.56), .00
Variable No. studies (patients) TUNA 
Difference in means
(% improvement)
VLAP 
Difference in means
(% improvement)
TUNA vs. VLAP 
WMD (95% CI), P value
Symptom score
Pre- 6 months 157 (30) -9 (47%) -7.3 (37%) -1.7 (-4.0,0.62), .15
Pre-1 year 157 (30) -11.2 (58%) -10.8 (55%) -0.4 (-2.48, 1.68), .70
Pre- 2 years 157 (30) -10 (52%) -12.9 (65%) 2.9 (1.3, 4.5), .00
Qmax (mL/s)
Pre- 6 months 157 (30) 4.3 (41%) 8.6 (141%) -4.3 (-6.17, -2.43),.00
Pre- 1 year 157 (30) 2.6 (30%) 7.8 (128%) -5.2 (-6.3, -3.57), .00
Pre- 2 years 157 (30) 2.3 (44%) 5.6 (92%) -3.3 (-4.7, -1.8), .00
PVR (mL)
Pre- 6 months 157 (30) -44 (62%) -63 (67%) 19 (1.90, 36.1), .02
Pre- 1 year 157 (30) -53 (62%) -64 (68%) 11 (-6.44, 28.44), .2
Pre- 2 years 157 (30) -55 (54%) -68 (72%) 13 (-5.6, 31.6), .17
Variable No. studies (patients) TUNA 
Difference in means
(% improvement)
HIFU 
Difference in means
(% improvement)
TUNA vs. HIFU
WMD (95% CI), P value
Table 6: TUNA vs. other minimally invasive therapies. Efficacy (Continued)BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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Symptom score
Pre- 6 months 157 (35) -9 (47%) -8.3 (56%) -0.7 (-2.35, 0.95), .40
Pre- 1 year 157 (35) -11.2 (58%) -10.4 (71%) -0.8 (-2.11, 0.51), .23
Pre- 2 years 157 (35) -10 (52%) -7 (48%) -3.0 (-4.71, -1.29), .00
Qmax (mL/s)
Pre- 6 months 157 (35) 4.3 (41%) 3.9 (42%) 0.40 (-9.4, 1.74), .55
Pre- 1 year 157 (35) 2.6 (30%) 3.9 (42%) -1.30 (-2.16, -0.44), .00
Pre- 2 years 157 (35) 2.3 (44%) 2 (22%) 0.30 (-0.52, 1.12), .47
PVR (mL)
Pre- 6 months 157 (35) -44 (62%) -48 (51%) 4.00(-10.44, 18.44), .58
Pre- 1 years 157 (35) -53 (62%) -45 (48%) -8.00 (-22.44, 6.44), .27
Pre- 2 years 157 (35) -55 (54%) -36 (38%) -19 (33.69, -4.31), .01
Abbreviations. TUMT: Transurethral Microwave Thermotherapy. WIT: Water-induced Thermotherapy. ILC: Interstitial Laser Coagulation. TUVP: 
Transurethral Electrovaporization of the Prostate. VLAP: Visual Laser Ablation of the Prostate. HIFU: Transrectal High Intensity Focused 
Ultrasound.
WMD: Weighted mean difference. Qmax: Maximum urinary flow rate. PVR: Post-void residual volume. Pdet at Qmax: Detrusor presures at peak 
flow rate.
Table 6: TUNA vs. other minimally invasive therapies. Efficacy (Continued)
TUMT, WIT, ILC, TUVP, VLAP and HIFU met the inclu-
sion criteria. No study that compared the efficacy and
safety of TUNA with medical treatment was found in liter-
ature.
According to the data obtained, TUNA significantly
improves BPH parameters with respect to baseline values
with improvements being particularly noteworthy in
terms of symptomatic alleviation and quality of life
scores. In addition, TUNA seems to be a relatively safe
technique with minimal effects on sexual function, has
few anesthetic requirements, is of short duration and gen-
erates a short hospital stay. Against this, the greatest risks
posed by the technique lie in its high re-treatment rate
given that, in the long-term, a high proportion of patients
need a new therapeutic intervention, be it medical or sur-
gical, though the pre- or intra-operative variables associ-
ated with this need for re-treatment are as yet unknown.
Comparisons with TURP show that, except in the very
short-term when TUNA achieves a similar level of efficacy
specially in symptoms and quality of life scores, the
degree of improvement in respect of all subjective and
objective variables was significantly lower than of TURP
across time with differences being particularly noteworthy
in terms of objective variables. Additionally, in the case of
TUNA, the length of the benefit is less than that observed
among patients treated with TURP, with a significantly
greater number [OR: 7.44 (2.47, 22.43)] of TUNA patients
requiring new treatment for symptomatic BPH. It has to
be recognized, however, that the TURP re-treatment rate
found in this study is significantly lower than the figures
previously reported in literature [2,59].
Insofar as safety is concerned and though the description
of adverse effects was heterogeneous and in general
ambiguous, pooled analysis of the literature shows that
use of TUNA versus TURP entails a reduction in the abso-
lute risk of complications about 19% with an estimated
NNT of 5 to prevent a bad outcome. With regard to spe-
cific complications, the differences observed are particu-
larly notable in terms of postoperative hemorrhage and
sexual function disorders.
Although it has to be acknowledged that the body of evi-
dence on which this review is based is of only moderate-
low quality, its results indicate that while TUNA does not
reach the same level of efficacy as TURP, it can provide
adequate short-term symptom relief and improvement in
quality of life with low postoperative morbidity. In this
context, TUNA may be an attractive option for patients
with a high symptom index but a low degree of obstruc-
tion who choose a surgical form of therapy and/or in
those who wish to preserve their sexual function. Along
the same lines, and given that TUNA has fewer anesthetic
requirements than TURP, it may likewise be of special
interest among patients with a high anesthetic risk or in
those who do not wish to undergo general or regional
anesthesia. Additionally, this study shows that TUNA is of
short duration and generates a short hospital stay than
TURP. Indeed, TUNA reduced the length of stay in hospi-
tal by two days. These data, albeit indirect, suggest that itBMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
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could entail a reduction in costs vis-à-vis TURP therapy.
There is no, however, good evidence supporting that
TUNA registers a better cost-effectiveness ratio from a
social perspective as none of the studies located con-
ducted a formal cost-evaluation.
However, the usefulness of TUNA in symptomatic BPH
must balance all these potential advantages against its
high rate of re-treatment. This constitutes, in our opinion,
the fundamental limitation of the technique given that
duration of efficacy is a matter of vital importance to both
patient and healthcare system owing to the personal and
financial implications of the succession of treatments. In
addition, the high secondary-treatment rate of TUNA
should be taken into account both when analyzing if may
entail a saving of healthcare resources against TURP.
As against other minimally invasive therapies, results dif-
fer vis-à-vis the comparator, with TUNA appearing as
superior to some but similar or even inferior to others.
However, analysis of available literature revealed a
number of problems that hinder extrapolation of the
results to clinical practice. Firstly, there is the fact that
despite the extensive search performed, all studies found
have a non-randomized design with multiple compari-
sons being established, something that tends to hamper
evaluation. Secondly, some of the studies have a scant
sample size, which renders assessment of results that
much more difficult. Thirdly, half of them have an exces-
sively short duration thereby being unable to appraise the
long-tem efficacy of the techniques. Fourthly, there is an
obvious lack of replication of comparisons, which not
only prevented detailed evaluation of results but also dis-
coloured the consistency of the evidence. All these factors
make us concern about the current literature's capacity to
provide the evidence necessary to determine the role of
TUNA vis-à-vis other local forms of treatment for BPH and
strongly support the need for better clinical research.
Potential report limitations
It has to be recognized that publication bias is possible
and that, by not including unpublished studies, the bene-
ficial effects of the TUNA system may have been overesti-
mated. Nevertheless, we feel that any such bias would
necessarily have been minimized by the scope of and sys-
tematic strategy used in the search of the literature and are
confident that majority of the research conducted in this
field was successfully identified. So, in accordance with
some recommendations [19,22] we have made a broad
search of literature using at least three database sources
supplemented by other search strategies. In addition, we
have included both fully published studies and grey liter-
ature [60]. However, in line with prior reports we decided
not to include unpublished data from industry given both
the difficulties encountered in obtaining this information
and the recognition that the use of these data may not nec-
essarily reduce the bias in meta-analysis [60,61].
We also endeavored to reduce such biases by having the
studies separately evaluated by two independent review-
ers and using defined criteria for the purposes of study
inclusion and analysis but, in accordance with some
recent literature [60,62] we have not used funnel plots to
examine the possibility of publication bias given the lim-
itations and potential misleading results of these graphs.
The methodologic quality of the studies, and particularly
the high percentage of non-controlled case-series could
constitute another limitation of this study. This situation
is particularly common in surgery [63], where less than
Table 7: TUNA vs. other Minimally Invasive Therapies: adverse effects
TUNA TUMT ILC TUVP VLAP HIFU WIT
Erectile dysfunction 7 (20%) 6 (26%) 7 (18%) -- -- -- --
Epidydimitis 0 (0%) -- -- 0 (0%) -- -- --
Urethral stenosis -- -- -- 2 (15%) -- -- --
Retrograde ejaculation 9 (14%) -- 16(15%) 12 (92%) -- -- --
Fever -- -- 1(1.4%) 1 (7.7%) -- -- --
Transitory incontinence -- -- -- 2 (15%) -- -- --
Urinary infection -- -- -- 2 (15%) -- -- --
Urinary retention -- -- -- 1 (5.9%) -- -- 3 (24%)
Rehospitalization 1 (6.7%) -- -- 1 (5.9%) 1 (7%) 1 (5%) 4 (30.7%)
Irritative symptoms -- -- 30 (42%) -- -- -- --
Reduction in seminal volume -- -- 15 (21%) -- -- -- --
Hematuria 1 (6.8%) -- 25 (35.2%) 2 (11.8%) 0 (0%) 1 (5%) --
Dysuria 2 (8.3%) -- -- -- -- -- --
Change in sexual activity 0 (0%) -- -- -- -- -- --
Results are expressed as number of cases and percentages. Abbreviations. TUMT: Transurethral Microwave Thermotherapy. WIT: Water-induced 
Thermotherapy. ILC: Interstitial laser coagulation TUVP: Transurethral Electrovaporization of the prostate. VLAP: Visual Laser Ablation of the 
prostate. HIFU: Transrectal High Intensity Focused Ultrasound.BMC Urology 2006, 6:14 http://www.biomedcentral.com/1471-2490/6/14
Page 15 of 17
(page number not for citation purposes)
10% of the evidence sustaining surgical interventions
comes from randomized studies [64] and where system-
atic reviews play an essential role in evaluating new tech-
nologies [65].
Although we are aware of the potential difficulties and
limitations posed by such evidence, we completely agree
with recent publications highlighting the usefulness of
these studies for evaluating the efficacy and safety of ther-
apeutic devices and procedures [7,63-69]. The evaluation
of such studies in systematic reviews provides information
on the possible benefits and risks of the procedures and
on the limitations of the evidence supporting their use.
Such studies moreover help identify those techniques that
should be subjected to more rigorous evaluation, and
identify areas of uncertainty which otherwise would not
be addressed and which would allow some procedures to
be accepted and others rejected in clinical practice, on the
basis of individual appeal alone [65-68]. It is therefore not
surprising that a large percentage of systematic reviews
conducted by organizations of repute [63,68] include
studies of case series, or that over 50% of all meta-analyses
in the literature correspond to non-randomized studies
[69]. Furthermore, the results of recent studies suggest
that non-randomized and randomized trials may yield
similar estimations of the effects of a given treatment [70]
and that meta-analyses of non-randomized studies may
produce results similar to those of meta-analyses of rand-
omized clinical trials [21].
Here we have to say that we have tried to reduce the pos-
sible impact of the studies' design using a conservative
random-effects model to combine the results of the indi-
vidual reports in the meta-analysis [71], and that sensitiv-
ity analysis by excluding poorer quality studies in
comparisons with TURP did not change our results. How-
ever, one of the main problems of the existing studies on
TUNA is the absence of independent evaluation of the
results obtained. To this we must also add that the
number of losses was not reported in a fair number of
studies. Consequently, it has to be recognized that detec-
tion and attrition biases may have influenced to some
degree the results of the review [19,72].
A further problem could reside, in our opinion, in the fact
that possible bias in the subjective variables might lead to
the beneficial effects of TUNA being overestimated. In
clinical drug trials, it has been observed that this effect is
blocked by administering a course of placebo-based ther-
apy to patients prior to the start of the study [73]. Yet, the
studies included make no mention of such a measure hav-
ing been taken, so that the influence of such a placebo
effect on the results cannot be ruled out, an effect that is
known to cause an improvement in symptoms and other
functional parameters, such as Qmax, as well as clinically
important adverse effects [73].
Conclusion
Despite these limitations, the results of this review suggest
that TUNA is a relatively effective and safe technique that
may eventually prove to have a role in selected patients
with symptomatic BPH. TUNA significantly improves
BPH parameters with respect to baseline values, but it
does not reach the same level of efficacy and long-lasting
success as TURP. On the other hand, TUNA seems to be
superior to TURP in terms of associated morbidity, anes-
thetic requirements and length of hospital stay. With
respect to the role of TUNA vis-à-vis other minimally inva-
sive forms of treatment, the results of this review indicate
that there are insufficient data to define this with any
degree of accuracy.
In addition, the review of the literature highlights the
existence of a number of areas of uncertainty, chief among
which, in our opinion, are: the precise mechanism of
action of the technique and the factors implicated in the
treatment's success; the lack of comparative studies with
respect to medical treatment; the position of TUNA with
respect to other minimally invasive therapies; and the
overall cost-effectiveness ratio of the technique. Such data
would be of critical importance to determine the exact
role of TUNA in the treatment of symptomatic BPH.
Implications for practice & policy
Apart from the need for the controlled clinical research
and sound methodologic quality that would resolve the
above-mentioned uncertainties, the following elements
should be borne in mind before TUNA is sought to be
introduced into routine clinical practice. Firstly, with
regard to its indication, current evidence show that the
potential advantages of TUNA in terms of morbidity and
anesthetic requirements should be balanced with the fact
that it does not reach the same level of efficacy and long-
lasting success as TURP. Secondly, due to the fact that it
has a greater impact on symptoms and less-pronounced
impact on obstructive parameters, TUNA would appear to
be especially indicated in the early stages of BPH. Never-
theless, the optimal point in the course of BPH progres-
sion for performing the technique has not yet been
identified. Thirdly, account must be taken of the high re-
treatment rate when the results of the procedure are pre-
sented in terms of use of healthcare resources.
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